Myriad Genetics to Present at the 37th Annual J.P. Morgan Healthcare Conference
December 27 2018 - 07:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that Mark C.
Capone, president and CEO, Myriad Genetics, is scheduled to present
at the 37th annual J.P. Morgan Healthcare Conference at 4:00 p.m.
PT (7:00 pm ET) on January 7, 2019, at the Westin St. Francis in
San Francisco, Calif. The presentation will be available to
interested parties through a live audio webcast accessible through
a link in the investor information section of Myriad’s website at
www.myriad.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: build upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website:
www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
Prelude and ForeSight are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Media Contact:Ron Rogers (801) 584-3065
rrogers@myriad.com
Investor Contact:Scott Gleason(801)
584-1143sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2023 to Mar 2024